SecBot SecBot
Biotech Drug Report Generated Sep 1, 2026

lonapegsomatropin

ASND·Ascendis Pharma
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval August 2021)
Why 4/10
Skytrofa is already FDA-approved and commercially marketed with no pending regulatory decision. The next hard catalyst would be a potential FDA filing for adult GHD indication, but no submission date has been announced. As an approved drug with no imminent binary catalyst, the impact score is capped at 4 per the rubric.
Actionable Insight NEUTRAL

Skytrofa is a steady commercial contributor but not the primary value driver for ASND anymore, YORVIPATH's rapid growth and the YUVIWEL launch are the main catalysts. Watch for any FDA filing for adult GHD indication (completed Phase 3 data in hand) and quarterly Skytrofa sales trajectory. The stock's next major binary catalyst is the EU MAA decision for YUVIWEL expected in Q4 2026.

Price Chart

Loading chart...

Executive Summary

Lonapegsomatropin (brand name Skytrofa) is Ascendis Pharma's once-weekly prodrug of human growth hormone, approved by the FDA in August 2021 for pediatric growth hormone deficiency (GHD). It uses Ascendis's TransCon technology to enable weekly dosing versus daily injections with standard somatropin. Skytrofa generated €55M in Q2 2026 revenue (+105% YoY total product revenue), but it is now the #2 commercial product for ASND behind YORVIPATH (€252M). Phase 3 trials in adult GHD are completed, though no FDA filing for that indication has been announced. The drug faces competition from daily somatropin generics and other long-acting GH products. ASND is a multi-product commercial-stage biotech with strong analyst support (mean target $315, ~19% upside), but the stock's thesis is increasingly driven by YORVIPATH and the newly launched YUVIWEL rather than Skytrofa alone.

How It Works

Lonapegsomatropin is a long-acting prodrug of somatropin (human growth hormone). It uses Ascendis's TransCon technology to temporarily attach an inert carrier molecule to the growth hormone, allowing it to circulate in the body longer before being released. This enables once-weekly injections instead of the standard daily shots required by conventional growth hormone drugs, reducing the treatment burden for patients with growth hormone deficiency.

Trial Status

FDA-approved in August 2021 for pediatric growth hormone deficiency based on pivotal Phase 3 trials (NCT02781727, NCT03305016) showing non-inferior efficacy to daily somatropin. Two Phase 3 trials in adults with GHD (NCT04615273, NCT05171855) are completed with results available, but no FDA submission for adult indication has been announced as of mid-2026.

The Two-Sided Case

▲ Bull Case5
Once-weekly dosing is a clear convenience advantage over daily somatropin injections, supporting market share gains in pediatric GHD.
Skytrofa generated €55M in Q2 2026 revenue as part of ASND's total €315M product revenue (+105% YoY), showing commercial traction.
Completed Phase 3 adult GHD trials provide a potential label expansion opportunity that could double the addressable market.
Director Jean Jacques Bienaime bought ~$493K of ASND shares in mid-August 2026, signaling insider confidence.
Analyst consensus is Strong Buy (25 of 26 analysts rate Buy/Strong Buy) with a mean price target of $315.17, implying ~19% upside.
▼ Bear Case5
Skytrofa faces competition from established daily somatropin products (Genotropin, Norditropin) and other long-acting GH products, limiting pricing power.
Multiple large institutional holders (FMR, Capital World, Morgan Stanley, Goldman Sachs) fully exited ASND positions in Q2 2026, signaling potential concern about valuation or competitive positioning.
Skytrofa is now the #2 product for ASND behind YORVIPATH (€252M vs €55M in Q2), meaning the stock's thesis is less dependent on this drug.
No FDA filing for adult GHD indication has been announced despite completed Phase 3 data, creating uncertainty on timing and label expansion path.
Weighted short-volume ratio was elevated at ~48% over the recent 58-session period, indicating elevated bearish positioning.

Upcoming Catalysts

  • Potential FDA filing for adult GHD indication (Phase 3 data complete)
  • Quarterly Skytrofa revenue reports as commercial adoption scales

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ascendis Pharma Press Release ASND ·Originating report

Sources · 5

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 sec.gov5 sec.gov